{"id":"paxg","safety":{"commonSideEffects":[{"rate":"null","effect":"Pneumonitis"},{"rate":"null","effect":"Hypothyroidism"},{"rate":"null","effect":"Hyperthyroidism"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"PAXG works by binding to the PD-1 receptor, which is a protein on the surface of immune cells. This binding blocks the interaction between PD-1 and its ligands, leading to the activation of immune cells and the enhancement of anti-tumor responses.","oneSentence":"PAXG is a drug that targets the PD-1 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:00.024Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"},{"name":"Head and neck squamous cell carcinoma"}]},"trialDetails":[{"nctId":"NCT04605913","phase":"PHASE1, PHASE2","title":"Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2022-04-01","conditions":"Pancreas Cancer, Metastatic Pancreatic Cancer, Pancreatic Adenocarcinoma","enrollment":40},{"nctId":"NCT05821556","phase":"PHASE2","title":"Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients","status":"RECRUITING","sponsor":"National Cancer Institute, Naples","startDate":"2023-06-12","conditions":"Adenocarcinoma of the Pancreas","enrollment":240},{"nctId":"NCT04793932","phase":"PHASE3","title":"Short-course Versus Long-course Pre-operative Chemotherapy With mFOLFIRINOX or PAXG (CASSANDRA TRIAL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Associazione Italiana per lo Studio del Pancreas","startDate":"2020-11-03","conditions":"Pancreas Ductal Adenocarcinoma","enrollment":261},{"nctId":"NCT04480268","phase":"PHASE4","title":"PAXG Out in the Country","status":"UNKNOWN","sponsor":"IRCCS San Raffaele","startDate":"2020-07-08","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":175},{"nctId":"NCT01730222","phase":"PHASE1, PHASE2","title":"A Phase I-II Study of PAXG in Stage III-IV Pancreatic Adenocarcinoma","status":"COMPLETED","sponsor":"IRCCS San Raffaele","startDate":"2012-11","conditions":"Pancreatic Cancer","enrollment":137}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":22,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"PAXG","genericName":"PAXG","companyName":"Associazione Italiana per lo Studio del Pancreas","companyId":"associazione-italiana-per-lo-studio-del-pancreas","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PAXG is a drug that targets the PD-1 receptor. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}